Annual EBITDA
-$34.38 M
-$18.08 M-110.84%
December 31, 2023
Summary
- As of February 17, 2025, CADL annual EBITDA is -$34.38 million, with the most recent change of -$18.08 million (-110.84%) on December 31, 2023.
- During the last 3 years, CADL annual EBITDA has fallen by -$21.29 million (-162.57%).
- CADL annual EBITDA is now -308.22% below its all-time high of -$8.42 million, reached on December 31, 2019.
Performance
CADL EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$9.91 M
+$11.51 M+53.72%
September 30, 2024
Summary
- As of February 17, 2025, CADL quarterly EBITDA is -$9.91 million, with the most recent change of +$11.51 million (+53.72%) on September 30, 2024.
- Over the past year, CADL quarterly EBITDA has stayed the same.
- CADL quarterly EBITDA is now -494.36% below its all-time high of -$1.67 million, reached on March 31, 2020.
Performance
CADL Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$48.83 M
-$2.39 M-5.15%
September 30, 2024
Summary
- As of February 17, 2025, CADL TTM EBITDA is -$48.83 million, with the most recent change of -$2.39 million (-5.15%) on September 30, 2024.
- Over the past year, CADL TTM EBITDA has stayed the same.
- CADL TTM EBITDA is now -2827.58% below its all-time high of -$1.67 million, reached on March 31, 2020.
Performance
CADL TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
CADL EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -110.8% | 0.0% | 0.0% |
| 3 y3 years | -162.6% | 0.0% | 0.0% |
| 5 y5 years | -308.2% | 0.0% | 0.0% |
CADL EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -110.8% | at low | -181.1% | +53.7% | -105.8% | at low |
| 5 y | 5-year | -308.2% | at low | -494.4% | +53.7% | -2827.6% | at low |
| alltime | all time | -308.2% | at low | -494.4% | +53.7% | -2827.6% | at low |
Candel Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$9.91 M(-53.7%) | -$48.83 M(+5.2%) |
| Jun 2024 | - | -$21.42 M(+192.5%) | -$46.44 M(+37.6%) |
| Mar 2024 | - | -$7.32 M(-28.0%) | -$33.75 M(-1.8%) |
| Dec 2023 | -$34.38 M(+110.8%) | -$10.17 M(+35.3%) | -$34.38 M(+20.7%) |
| Sep 2023 | - | -$7.52 M(-13.9%) | -$28.50 M(-1.5%) |
| Jun 2023 | - | -$8.73 M(+9.8%) | -$28.94 M(+21.9%) |
| Mar 2023 | - | -$7.96 M(+85.7%) | -$23.73 M(-3.5%) |
| Dec 2022 | -$16.31 M | -$4.28 M(-46.2%) | -$24.60 M(-11.3%) |
| Sep 2022 | - | -$7.96 M(+125.8%) | -$27.73 M(+0.3%) |
| Jun 2022 | - | -$3.53 M(-60.0%) | -$27.64 M(-4.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | -$8.82 M(+19.0%) | -$28.80 M(+17.9%) |
| Dec 2021 | -$24.42 M(+86.5%) | -$7.41 M(-5.9%) | -$24.42 M(+6.3%) |
| Sep 2021 | - | -$7.88 M(+68.0%) | -$22.97 M(+30.2%) |
| Jun 2021 | - | -$4.69 M(+5.6%) | -$17.65 M(+14.5%) |
| Mar 2021 | - | -$4.44 M(-25.6%) | -$15.41 M(+21.9%) |
| Dec 2020 | -$13.10 M(+55.5%) | -$5.97 M(+134.0%) | -$12.64 M(+89.4%) |
| Sep 2020 | - | -$2.55 M(+3.9%) | -$6.67 M(+61.8%) |
| Jun 2020 | - | -$2.46 M(+47.2%) | -$4.12 M(+147.2%) |
| Mar 2020 | - | -$1.67 M | -$1.67 M |
| Dec 2019 | -$8.42 M | - | - |
FAQ
- What is Candel Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Candel Therapeutics?
- What is Candel Therapeutics annual EBITDA year-on-year change?
- What is Candel Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Candel Therapeutics?
- What is Candel Therapeutics quarterly EBITDA year-on-year change?
- What is Candel Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Candel Therapeutics?
- What is Candel Therapeutics TTM EBITDA year-on-year change?
What is Candel Therapeutics annual EBITDA?
The current annual EBITDA of CADL is -$34.38 M
What is the all time high annual EBITDA for Candel Therapeutics?
Candel Therapeutics all-time high annual EBITDA is -$8.42 M
What is Candel Therapeutics annual EBITDA year-on-year change?
Over the past year, CADL annual EBITDA has changed by -$18.08 M (-110.84%)
What is Candel Therapeutics quarterly EBITDA?
The current quarterly EBITDA of CADL is -$9.91 M
What is the all time high quarterly EBITDA for Candel Therapeutics?
Candel Therapeutics all-time high quarterly EBITDA is -$1.67 M
What is Candel Therapeutics quarterly EBITDA year-on-year change?
Over the past year, CADL quarterly EBITDA has changed by $0.00 (0.00%)
What is Candel Therapeutics TTM EBITDA?
The current TTM EBITDA of CADL is -$48.83 M
What is the all time high TTM EBITDA for Candel Therapeutics?
Candel Therapeutics all-time high TTM EBITDA is -$1.67 M
What is Candel Therapeutics TTM EBITDA year-on-year change?
Over the past year, CADL TTM EBITDA has changed by $0.00 (0.00%)